GnRH Agonists for Endometriosis: How Suppression Treats Pain
GnRH and Endometriosis
50-90% pain relief
Clinical trials of GnRH agonists for endometriosis consistently show pain relief in 50-90% of patients, though the hypoestrogenic state limits monotherapy to six months.
Paoletti et al., Expert Opinion on Drug Metabolism and Toxicology, 2025
Paoletti et al., Expert Opinion on Drug Metabolism and Toxicology, 2025
View as imageEndometriosis affects an estimated 190 million women and transgender men worldwide, roughly 10% of those of reproductive age. The condition involves endometrial-like tissue growing outside the uterus, forming lesions that respond to estrogen by proliferating, bleeding, and triggering chronic inflammation and pain. GnRH agonists treat endometriosis by exploiting a pharmacological paradox: continuous stimulation of the pituitary GnRH receptors leads to their downregulation, shutting off the hormonal cascade that drives estrogen production.[1] Three GnRH agonists, leuprolide acetate (depot injection), goserelin (implant), and nafarelin (intranasal), have FDA approval for endometriosis treatment. Pain relief occurs in 50-90% of patients across clinical trials, but the induced hypoestrogenic state causes bone mineral density loss that restricts monotherapy to six months.[1] Add-back hormone therapy extends this window to twelve months. Newer oral GnRH antagonists like elagolix and relugolix are changing this treatment landscape. This article examines how GnRH agonists work, what the clinical evidence shows, and where the field is moving.
Key Takeaways
- GnRH agonists induce hypoestrogenism through pituitary receptor downregulation, with estrogen suppression beginning after an initial 10-12 day flare-up period (Paoletti et al., Expert Opinion on Drug Metabolism and Toxicology, 2025)
- Clinical trials show 50-90% pain relief for dysmenorrhea, pelvic pain, and dyspareunia across leuprolide, goserelin, and nafarelin preparations
- Bone mineral density loss limits GnRH agonist monotherapy to 6 months, but add-back therapy with low-dose estrogen and progestin extends treatment to 12 months while maintaining efficacy
- The target estradiol level of 40-50 pg/mL suppresses endometriotic growth while minimizing bone loss, a concept called the "estrogen threshold hypothesis"
- CGRP/RAMP1 signaling from sensory nerves drives endometriosis pain and lesion growth; FDA-approved CGRP-blocking drugs reduced both pain and lesion size in mice (Fattori et al., Science Translational Medicine, 2024)
- Oral non-peptide GnRH antagonists achieve rapid, dose-dependent suppression without the flare-up effect or need for injection, representing the next generation of hormonal endometriosis treatment
The GnRH Agonist Paradox: Stimulation That Leads to Suppression
GnRH (gonadotropin-releasing hormone) is a decapeptide released in pulses from the hypothalamus. Each pulse triggers the pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn stimulate ovarian estrogen production. The pulsatile pattern is essential: the pituitary GnRH receptors require periodic rest to reset their signaling capacity.[2]
GnRH agonists exploit this requirement by providing continuous rather than pulsatile stimulation. During the first 10-12 days of treatment, continuous receptor activation produces an initial surge in FSH, LH, and estrogen, called the flare-up effect. This can temporarily worsen endometriosis symptoms. After this phase, the continuously stimulated pituitary GnRH receptors downregulate, reducing their number and sensitivity. FSH and LH production drops, ovarian estrogen production falls to postmenopausal levels, and estrogen-dependent endometriotic tissue begins to regress.[1]
This mechanism is fundamentally different from GnRH antagonists, which directly block GnRH receptors without any initial stimulation phase. Peptide GnRH antagonists like cetrorelix and ganirelix achieve immediate suppression but still require injection. Non-peptide GnRH antagonists like elagolix and relugolix combine immediate onset with oral dosing, a pharmacological advance discussed in more depth in our article on oral GnRH antagonists for endometriosis.[2]
Clinical Evidence: Three Approved GnRH Agonists
Leuprolide Acetate (Lupron Depot)
Leuprolide is the most widely used GnRH agonist for endometriosis. Administered as a monthly intramuscular depot injection (3.75 mg) or a three-month formulation (11.25 mg), it achieves estrogen suppression within two to four weeks. A prospective randomized multicenter double-blind trial compared leuprolide depot 3.75 mg monthly to nafarelin 200 mcg intranasally twice daily over six months. Both treatments significantly reduced dysmenorrhea, pelvic pain, and pelvic tenderness scores compared to baseline, with no significant difference between the two agents.
The depot formulation technology that makes monthly dosing possible has continued to evolve. Leuprolide is a cationic peptide that strongly interacts with acid-terminated PLGA polymers, enabling sustained release from biodegradable microspheres. A 2025 study by Giles et al. optimized aqueous remote loading of leuprolide into PLGA microspheres, achieving continuous release over one month with low initial burst and developing a theoretical framework to predict encapsulation efficiency for other peptide drugs.[3] This type of formulation science is what enables patients to receive one injection per month rather than daily dosing.
Goserelin (Zoladex)
Goserelin is administered as a subcutaneous implant in the anterior abdominal wall that releases the drug over one month (3.6 mg) or three months (10.8 mg). The implant is a solid cylinder approximately 1 mm in diameter that does not require removal; it biodegrades in situ. Clinical trials showed goserelin produced pain relief comparable to danazol (an older androgen-based treatment) but without the hyperandrogenic side effects that make danazol poorly tolerated: acne, weight gain, deepening voice, and hirsutism. Comparative studies demonstrated similar improvements in dysmenorrhea, deep dyspareunia, and nonmenstrual pelvic pain between goserelin and continuous low-dose oral contraceptives, though goserelin achieved more complete estrogen suppression.[1]
Nafarelin (Synarel)
Nafarelin is administered intranasally at 200 mcg twice daily, making it the only non-injectable GnRH agonist for endometriosis. A multicenter trial showed that reduction in pain scores and symptom recurrence rates were similar after three versus six months of nafarelin therapy, with 26% of patients in each group requiring retreatment for recurrent symptoms. The three-month course relieved symptoms as effectively as six months, though the longer duration delayed symptom recurrence.[1]
Bone Density Loss and Add-Back Therapy
The most significant limitation of GnRH agonist therapy is bone mineral density (BMD) loss from estrogen deprivation. Estrogen plays a critical role in bone metabolism by suppressing osteoclast activity (the cells that break down bone). When estrogen drops to postmenopausal levels during GnRH agonist therapy, osteoclast activity increases and bone resorption outpaces bone formation. The lumbar spine is particularly vulnerable, with BMD losses of 2-8% documented after six months of GnRH agonist monotherapy in clinical trials. This is why GnRH agonist monotherapy is limited to six months.
Other hypoestrogenic side effects compound the bone concern. Hot flashes occur in 70-80% of patients and can be severe enough to disrupt sleep and daily functioning. Vaginal dryness, mood changes, headaches, and decreased libido are also common. These side effects mirror those of natural menopause, which makes sense given that GnRH agonists create a pharmacological menopause.
The Estrogen Threshold Hypothesis
Add-back therapy was developed based on a critical observation: endometriotic tissue requires higher estrogen levels to proliferate than bone requires to maintain its density. By providing low-dose estrogen and progestin alongside the GnRH agonist, clinicians can maintain estradiol at approximately 40-50 pg/mL, a level sufficient to protect bone and reduce vasomotor symptoms but insufficient to stimulate endometriotic growth.[1] This concept, called the estrogen threshold or estrogen window hypothesis, provides the pharmacological rationale for the entire add-back approach.
Clinical trials confirmed that add-back therapy with norethindrone acetate (5 mg daily), alone or combined with low-dose conjugated estrogen (0.625 mg daily), preserved bone density without diminishing the pain relief achieved by the GnRH agonist. This extends the safe treatment window from six to twelve months. Studies in adolescent patients confirmed that bone density changes with GnRH agonist plus add-back therapy were modest and largely reversible after treatment cessation, an important finding given that adolescents are still accumulating peak bone mass.
However, even with add-back therapy, treatment duration remains limited. GnRH agonist therapy is not considered a permanent solution; symptoms typically return within months to years of discontinuation. In a long-term follow-up study, approximately one-third of patients required additional treatment within two years of stopping GnRH agonist therapy. This recurrence pattern has driven the search for treatments that address the underlying disease mechanism rather than simply suppressing estrogen.
Beyond Estrogen: How Neuropeptides Drive Endometriosis Pain
The classical view of endometriosis pain is straightforward: estrogen drives lesion growth, lesions cause inflammation, inflammation causes pain. Recent peptide research reveals a more complex picture in which sensory nerves actively participate in disease progression through neuropeptide signaling.
CGRP: Pain Signaling That Grows Lesions
In a landmark 2024 study published in Science Translational Medicine, Fattori et al. demonstrated that calcitonin gene-related peptide (CGRP) released by nociceptors (pain-sensing neurons) drives both endometriosis pain and lesion growth. Using human endometriosis samples from eight patients and a mouse model, the researchers showed that CGRP polarizes macrophages into a "pro-endometriosis" phenotype that promotes endometrial cell proliferation. Ablation of nociceptors reduced pain, monocyte recruitment, and lesion size. Treatment with FDA-approved drugs that block CGRP-RAMP1 signaling (drugs already approved for migraine) reduced mechanical hyperalgesia, spontaneous pain, and lesion size in mice.[4]
The same group subsequently identified IL-33 as the key mediator released by CGRP-stimulated macrophages. Anti-IL-33 antibody treatment reduced both pain and lesion size in their mouse model, and IL-33 expression in human lesion macrophages correlated with genetic risk of endometriosis.[5]
Substance P and CGRP: Driving Fibrosis
Yan et al. (2019) demonstrated that substance P and CGRP, acting through their respective receptors NK1R and CRLR/RAMP-1, induced a cascade of cellular transformations in endometriotic tissue: epithelial-mesenchymal transition, fibroblast-to-myofibroblast transdifferentiation, and conversion of stromal cells into smooth muscle cells. This cascade produced fibrosis. Neutralizing NK1R and/or CGRP receptors blocked these processes. Deep endometriosis lesions showed significantly higher nerve fiber density, receptor expression, and fibrotic content than ovarian endometriomas.[6]
Nociceptin/Orphanin FQ: A New Target
Guan et al. (2023) identified nociceptin/orphanin FQ (NOP) receptor expression in endometriosis-associated nerve fibers for the first time. Peritoneal samples from 94 symptomatic women (73 with endometriosis, 21 controls) showed that NOP was often colocalized with substance P, CGRP, tyrosine hydroxylase, and vasoactive intestinal peptide-positive nerve fibers. NOP expression was increased in endometriosis-associated nerve fibers compared to controls.[7] The nociceptin/OFQ system is distinct from the classical opioid peptide system and does not produce the tolerance and addiction concerns associated with mu opioid receptor targeting. NOP agonists are already in clinical trials for other chronic pain conditions, making this a potential near-term therapeutic opportunity for endometriosis.
Brain-Level Changes
Torres-Reverón et al. (2016) showed that endometriosis alters central pain processing. In a rat model, endometriosis reduced mu opioid receptor immunoreactivity by 20% and NMDA receptor NR1 profiles by 40% in the ventral periaqueductal gray (PAG), a brain region critical for pain modulation. These changes occurred without alterations in endogenous opioid peptide levels, suggesting that endometriosis impairs the brain's capacity to modulate pain through receptor downregulation rather than peptide depletion.[8]
These findings collectively suggest that endometriosis pain is not simply a consequence of inflammation but involves active neuropeptide-driven pathways that can be independently targeted. The clinical implications are substantial: GnRH agonists suppress estrogen to reduce lesion growth, but they do not directly address the neuropeptide-driven pain circuits. This may explain why some patients continue to experience pain even with adequate estrogen suppression, and why pain sometimes persists after lesions have been surgically removed. Targeting both the hormonal and neuropeptide axes simultaneously could produce more complete symptom relief. For a broader view of peptide-based treatment strategies, see our article on peptide-based approaches to endometriosis.
Postoperative Use of GnRH Agonists
GnRH agonists are frequently used after surgical excision of endometriosis lesions to extend the symptom-free period. Meta-analyses have demonstrated that postoperative GnRH agonist therapy delays symptom recurrence compared to expectant management alone, though it does not eliminate the risk of recurrence entirely.
The rationale is straightforward: surgery removes visible lesions but microscopic endometriotic tissue often remains. Postoperative estrogen suppression with GnRH agonists targets these residual implants during the window when they are most vulnerable. A typical protocol involves three to six months of GnRH agonist therapy beginning within the first month after surgery.
The evidence for postoperative GnRH agonist use in improving fertility outcomes is less clear. While some studies suggest improved pregnancy rates after combined surgical-medical treatment, randomized trials have not consistently shown a fertility benefit from postoperative GnRH agonists. The extended period of ovulatory suppression may counteract any benefit from lesion reduction in patients actively trying to conceive.
An important consideration in postoperative GnRH agonist use is the timing of fertility attempts after treatment cessation. Ovulation typically resumes within four to twelve weeks of stopping GnRH agonist therapy, with the hypothalamic-pituitary-ovarian axis recovering its pulsatile GnRH secretion pattern. Some reproductive endocrinologists use a short course of GnRH agonist therapy (two to three months) before in vitro fertilization (IVF) cycles in endometriosis patients, based on the theory that pre-treatment estrogen suppression improves the uterine environment for embryo implantation. The evidence for this approach is mixed, with some meta-analyses showing improved IVF outcomes and others showing no benefit.
Who Should and Should Not Use GnRH Agonists
GnRH agonist therapy is generally reserved for patients with moderate to severe endometriosis who have not responded to first-line treatments (NSAIDs combined with hormonal contraceptives or progestins). The strongest evidence supports their use for pain management rather than fertility enhancement.
Contraindications include known or suspected pregnancy, undiagnosed abnormal vaginal bleeding, and pre-existing conditions that would be worsened by estrogen deprivation (such as established severe osteoporosis). Patients with established low bone mineral density may be poor candidates unless add-back therapy is used from the start of treatment.
Age is a relevant consideration. In adolescent patients, GnRH agonists may be appropriate for severe disease unresponsive to other treatments, but the potential impact on peak bone mass acquisition requires careful monitoring. In perimenopausal patients approaching natural menopause, GnRH agonists are sometimes used as a bridge therapy with the expectation that natural estrogen decline will continue the therapeutic effect after drug cessation. For all patients, the decision to use GnRH agonists involves balancing the substantial pain relief they provide against the time-limited nature of treatment and the burden of hypoestrogenic side effects.
Next-Generation Peptide Approaches
GHRH Antagonists
Beyond GnRH-targeting, other peptide hormone axes are being explored. Köster et al. (2017) found growth hormone-releasing hormone (GHRH) receptor splice variant 1 (SV1) in endometriotic tissue, with highest expression in eutopic endometrium from endometriosis patients. The GHRH antagonist MIA-602 at 10 mcg daily significantly reduced endometrial xenotransplant size after four weeks in a mouse model and decreased endometrial stromal cell proliferation in vitro.[9]
Anti-Angiogenic Peptide Nanoparticles
Egorova et al. (2025) developed CXCR4-targeted peptide nanoparticles to deliver anti-VEGFA siRNA to endometriotic lesions in a rat model. The peptide-based carrier, composed of arginine-histidine-rich peptide coated with a CXCR4-targeting ligand, achieved significant reduction in endometrial implant growth and VEGFA gene silencing compared to saline controls.[10]
Oral GnRH Antagonists
Novel oral GnRH antagonists continue to emerge. Chi et al. (2025) reported a phase 2 trial of SHR7280, an oral GnRH antagonist, in 85 infertile women undergoing controlled ovarian hyperstimulation. At 200 mg twice daily, SHR7280 achieved 100% LH surge inhibition (95% CI 92-100) with a clinical pregnancy rate of 53% among patients receiving fresh embryo transfer. Treatment-related adverse events occurred in only 1% of patients.[11] While this trial focused on fertility applications, the oral GnRH antagonist platform may eventually be adapted for endometriosis treatment.
Separate research on leuprolide's oral delivery explored lipophilic complexation to enhance the peptide's penetration through enterocytes via the ER-Golgi pathway, bypassing lysosomal degradation and hepatic first-pass metabolism. The approach diverted leuprolide absorption through the lymphatic route, potentially offering oral delivery of the established agonist.[12]
GnRH Agonists vs. Antagonists: A Comparison
| Feature | GnRH Agonists | Peptide Antagonists | Oral Non-Peptide Antagonists |
|---|---|---|---|
| Onset of action | 10-12 days (flare-up first) | Immediate | Immediate |
| Route | Injection/implant/intranasal | Injection | Oral |
| Flare-up effect | Yes | No | No |
| Dose adjustability | Limited | Limited | High (dose-dependent) |
| Estrogen target | Full suppression (~20 pg/mL) | Full suppression | Partial or full (dose-dependent) |
| FDA-approved for endometriosis | Leuprolide, goserelin, nafarelin | None | Elagolix, relugolix |
The 2025 pharmacokinetic review by Paoletti et al. concluded that non-peptide oral GnRH antagonists offer the most important prospects for tailored endometriosis treatment, given their rapid onset, oral administration, and dose-dependent estrogen suppression that can be adjusted to balance pain relief against side effects.[1]
The comparative analysis by Patel et al. (2024) detailed how structural advances in third- and fourth-generation peptide GnRH antagonists (cetrorelix, ganirelix, degarelix, teverelix) have improved clinical safety profiles. Early peptide GnRH antagonists caused histamine release and injection site reactions that limited their clinical utility. Cetrorelix and ganirelix largely solved the histamine problem through structural modifications, and teverelix is emerging as a next-generation agent with an optimized balance of efficacy and safety. However, all peptide-based GnRH antagonists still require injection because peptides are degraded by gastrointestinal enzymes if taken orally.[2]
The non-peptide oral agents represent a fundamentally different pharmacological class that solves this delivery limitation. Elagolix (Orilissa), approved by the FDA in 2018 for endometriosis, was the first oral GnRH antagonist available for this indication. Relugolix, combined with estradiol and norethindrone acetate (marketed as Myfembree), followed with approval in 2021 for uterine fibroids and subsequently for endometriosis in some markets. Both drugs can achieve partial or full estrogen suppression depending on dose, allowing clinicians to titrate the degree of suppression against side effects for each individual patient.
The dose flexibility of oral antagonists is their most clinically relevant advantage beyond convenience. Elagolix at 150 mg once daily produces partial estrogen suppression (reducing estradiol to approximately 40-50 pg/mL), which is sufficient for pain relief in many patients while causing fewer bone and vasomotor side effects than full suppression. Elagolix at 200 mg twice daily achieves near-complete suppression comparable to GnRH agonists, reserved for patients with more severe disease. This dose-response relationship cannot be replicated with depot GnRH agonist formulations, which deliver a fixed dose over weeks to months.
The Bottom Line
GnRH agonists remain a well-established treatment for endometriosis-associated pain, with 50-90% efficacy across clinical trials. Their mechanism, pituitary downregulation leading to estrogen suppression, is effective but inherently limited by hypoestrogenic side effects. Add-back therapy extends safe use from six to twelve months. The emergence of oral non-peptide GnRH antagonists addresses both the delivery burden and the flare-up effect of agonists. Meanwhile, research into neuropeptide-driven pain mechanisms, particularly CGRP, substance P, and nociceptin signaling, is revealing treatment targets beyond the hormonal axis that could transform how endometriosis is managed.